• Alejandro de la Sierra and Anna Oliveras.
• Unidad de Hipertensión, Servicio de Medicina Interna, Hospital Mútua Terrassa. Universidad de Barcelona, Barcelona, España. Electronic address: asierra17583@gmail.com.
• Med Clin (Barc). 2024 Sep 27; 163 (6): 301305301-305.

AbstractEven though a large number of antihypertensive drugs are suitable for hypertension treatment, some new therapeutic targets are recently under development. Most are focused in the treatment of resistant hypertension, added to the drugs currently available for treating such condition. Others have specific particularities in their duration of action, which allows their use once per month or every six months and could become alternatives to the current antihypertensive treatment. Most interesting therapeutic targets are the renin-angiotensin-aldosterone system, through interference with the RNA of the angiotensinogen, the inhibition of brain aminopeptidase III, the inhibition of aldosterone synthase, and new non-steroidal aldosterone receptor antagonists. In addition, dual endothelin receptor antagonists or agonists of the NPR1 receptor, the main effector of natriuretic peptides are other new interesting therapeutic possibilities. In this paper, we review clinical data on the development of the most interesting molecules acting through these new therapeutic targets.Copyright © 2024 Elsevier España, S.L.U. All rights reserved.

24 keywords...

hide…